Last reviewed 2026-04-23 · How we verify

PF-06410293

PF-06410293 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.

PF-06410293 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Psoriasis, Atopic dermatitis.

At a glance

Mechanism of action

By inhibiting PDE4, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated intracellular cAMP in immune and inflammatory cells. This elevation suppresses the production of pro-inflammatory cytokines and chemokines, thereby reducing inflammation. PDE4 inhibition has been explored for various inflammatory and immune-mediated conditions.

Approved indications

• Psoriasis
• Atopic dermatitis

Common side effects

• Nausea
• Diarrhea
• Headache
• Vomiting

Key clinical trials

• A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis (PHASE3)
• A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02). (PHASE3)
• A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects (PHASE1)
• A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07)) (PHASE1)
• Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.